Pharmaceutical Companies

Orchestra BioMed Goes Public After $110 Million PE Fund Raise

February 2, 2023 - Orchestra BioMed was introduced on the Nasdaq Global Market this month after completing its combination with the special purpose acquisition company Health Sciences Acquisitions Corporation 2. Gross proceeds and the $110 million earned through series D financing are expected to carry the company through to 2026. Last year, Orchestra disclosed its...

Read More


More Articles

Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences

by Hayden Schmidt

At the beginning of this month, global healthcare firm Viatris Inc announced the completion of its Oyster Point Pharma and Famy Life Sciences acquisitions. The two companies will be combined, and...

Thermo Fisher Launches Medium to Support Cell, Gene Therapy

by Samantha McGrail

Thermo Fisher Scientific recently launched a GMP-manufactured cell culture medium that supports the large-scale growth and culture of functional natural killer (NK) cells for cell and gene...

Novartis Acquires Gene Therapy Company to Expand Portfolio

by Samantha McGrail

Novartis recently acquired Arctos Medical to add a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Optogenetics has...

Recent Articles